Purine-Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors.

ABSTRACT: Background/Objectives: The dual targeting of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) represents an effective approach for cancer treatment. The current study involved the design, synthesis, and biological evaluation of a new series of purine-containing hydrazones, 6-24 (a,b), as anticancer agents targeting EGFR and HER2 kinases. Methods: The proposed compounds were initially screened in silico using molecular docking to investigate their binding affinity to the active sites of EGFR and HER2 kinase domains. Subsequently, the compounds were synthesized and evaluated in vitro for their antiproliferative activity, using the MTT assay, against the various cancer cell lines A549, SKOV-3, A2780, and SKBR

SUBMITTER: Albalawi FS 

PROVIDER: S-EPMC12299904 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature